The usefulness of continuous administration of hypoxic cytotoxin combined with mild temperature hyperthermia, with reference to effects on quiescent tumour cell populations.
To evaluate the usefulness of continuous administration of hypoxic cytotoxins in terms of targeting acute hypoxia in solid tumours and the significance of combination with mild temperature hyperthermia (MTH) (40 degrees C, 60 min), the cytotoxic effects of singly or continuously administered tirapazamine (TPZ) and TX-402 were examined in combination with or without MTH in vivo. Further, the effects were also analysed on total (=proliferating (P)+quiescent (Q)) and Q cell populations in solid tumours with the method for selectively detecting the Q cell response. C3H/He mice bearing SCC VII tumours received a continuous administration of 5-bromo-2'-deoxyuridine (BrdU) for 5 days to label all P cells. The tumour-bearing mice then received a single intra-peritoneal injection or 24 h continuous subcutaneous infusion of hypoxic cytotoxin, TPZ or TX-402, with or without MTH. On the other hand, to detect the changes in the hypoxic fraction (HF) in the tumours by MTH, another group of mice with or without MTH received a series of test doses of gamma-rays while alive or after tumour clamping. After each treatment, the tumour cells were isolated and incubated with a cytokinesis blocker (=cytochalasin-B) and the micronucleus (MN) frequency in cells without BrdU labelling (=Q cells) was determined using immunofluorescence staining for BrdU. The MN frequency in total tumour cells was determined from the tumours that were not pre-treated with BrdU. The sensitivity to TX-402 was slightly higher than that to TPZ in both total and Q tumour cells. Continuous administration elevated the sensitivity of both total and Q cells, especially total cells. MTH raised the sensitivity of Q cells more remarkably than that of total cells in both single and continuous administrations. It was thought to be probably because of the higher dose distribution of hypoxic cytotoxin in intermediately hypoxic areas derived mainly from chronic hypoxia through MTH. From the viewpoint of tumour control as a whole including both total and Q tumour cells, the continuous administration of hypoxic cytotoxin combined with MTH may be useful for sensitizing tumour cells in vivo.
Masunaga
S
S
Radiation Oncology Research Laboratory, Research Reactor Institute, Kyoto University, Sennan-gun, Osaka, Japan. smasuna@rri.kyoto-u.ac.jp
Nagasawa
H
H
Uto
Y
Y
Hori
H
H
Suzuki
M
M
Nagata
K
K
Kinashi
Y
Y
Ono
K
K
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001973:Bromodeoxyuridine; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000628:therapy*; D003131:Combined Modality Therapy; D003497:Cyclic N-Oxides / Q000627:therapeutic use*; D005260:Female; D005455:Fluorescent Antibody Technique; D006979:Hyperthermia, Induced / Q000379:methods*; D051379:Mice; D008809:Mice, Inbred C3H; D015162:Micronucleus Tests; D009368:Neoplasm Transplantation; D009369:Neoplasms / Q000188:drug therapy / Q000628:therapy*; D011810:Quinoxalines / Q000627:therapeutic use*; D000077704:Tirapazamine; D014227:Triazines / Q000627:therapeutic use*
C503709:3-amino-2-quinoxalinecarbonitrile; D000970:Antineoplastic Agents; D003497:Cyclic N-Oxides; D011810:Quinoxalines; D014227:Triazines; D000077704:Tirapazamine; D001973:Bromodeoxyuridine